Sector News

How can Teva buck industry trends for generics growth? Launches

September 12, 2016
Life sciences

Teva laid out its outlook for its newly bolstered generics business on Friday. And the way the company sees things, thanks to its pipeline, the road ahead is a rosy one.

Post-Allergan generics buy, Teva expects its copycat business to grow 5% per year, despite the volume decline and price erosion that are taking a toll on the industry, generics CEO Siggi Olafsson said on the call. And the company will secure those expansion numbers by launching 1,500 products per year that grow yearly revenue by about 10%.

That’s, of course, a pretty large number, representing four launches for every day of 2017, Olafsson noted. “We cannot miss a beat in that,” he told investors.

But Teva believes it has some key advantages over its competitors that’ll help it push full steam ahead in the pipeline department. The company argues that it’s more inclined than its competition toward first-to-file and first-wave products, which make up two-third of its portfolio. And for that reason, the FDA’s plan to accelerate approvals of first generics will be more beneficial than risky, the company figures.

As for right now, Teva has 320 products under FDA review and 325 in development; with those candidates, it’s taking aim at $200 billion in branded sales. It’s whether those pan out to that 5% growth rate that remains to be seen, Bernstein’s Ronny Gal pointed out in a note to clients.

On the other side of the coin, Teva’s also well-positioned to compete with its already marketed products, execs said, given its beefed-up scale and level of diversification. The $40 billion-plus buy strengthened Teva’s market position in key countries including the U.S., Canada, Russia and the U.K., and now, “buyers can’t avoid Teva,” Gal wrote.

Plus, “with the size of our portfolio, with the flexibility of our manufacturing network, with the industry leading position in the market, we are more shielded” from price fluctuations, Olaffson told investors.

But that doesn’t mean industry challenges won’t take their toll. “Teva is 18% of the U.S. generic business, and it is hard to outrun the industry trend when ‘you are the industry,’” Gal said. Teva’s industry projections are also optimistic, as Evercore ISI analyst Umer Raffat flagged in his own note to clients, calling them “meaningfully higher” than consensus estimates.

One thing’s for sure: With top-seller Copaxone under serious pressure from other knockoff-makers, Teva could use all the generics revenue it can get. Last week, the U.S. Patent and Trademark Office’s review board invalidated the third patent of three that have so far come up for its review on Teva’s new, long-acting version of the multiple sclerosis blockbuster. And while Teva still has a chance to defend itself in an upcoming court battle, some analysts–including Credit Suisse’s Vamil Divan–see the company as “more likely to lose than win.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.